BPC-157 and VEGFR2: preclinical research on blood vessel formation
Evidence level: Cell and animal research, with angiogenesis assays · Publication year: 2017
This overview discusses one original scientific publication on BPC-157. The source is indexed in PubMed, the literature database of the U.S. National Library of Medicine.
What was studied?
The study investigated whether BPC-157 affected angiogenesis and what role VEGFR2 played in this process. Researchers combined endothelial cell assays with experimental models of reduced blood flow.
What did the researchers find?
The publication reported increased angiogenic activity and increased VEGFR2 expression. In the cell models used, no corresponding increase in VEGF-A was observed.
What are the limitations?
These are preclinical observations. Increased angiogenesis is not beneficial in every context and does not prove safety or efficacy for human injuries.
Significance for research
The study distinguishes changes in a receptor from changes in the associated growth-factor signal.
Official source
Original publication via PubMed — PMID 27847966
Research Use Only. This literature summary does not provide treatment or usage advice. Research on a molecule is not evidence of the efficacy, safety, or purity of a Peptidera product. PubMed indexing is not product approval.
Related research products
View product specifications and available batch documentation. The studies discussed were not conducted with Peptidera products and do not prove the efficacy of our products. For laboratory research only; not for human or animal consumption.